Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Drug Review Review Pathway

Another EU Filing Targets Burgeoning NMOSD Market

  • News

Executive Summary

Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.

You may also be interested in...



Lengthy EU Regulatory Review Ends Well For Roche’s NMOSD Therapy

The European Medicines Agency has finally recommended pan-EU marketing approval for Roche’s Enspryng.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Migraine & Hepatitis B Prevention Products Among New EU Filings

The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.

Table

View full table

Related Content

Scrip
Pink Sheet

Topics

Related Companies

Tags:
Europe Drug Review Review Pathway
Latest Headlines

Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza

House QALY Bill Overreach Threatens Medicare Price Negotiation Program, Democrats Warn

Recent And Upcoming FDA Advisory Committee Meetings

iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements

See All
UsernamePublicRestriction

Register

PS143602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By